![Jean-Paul Laurin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jean-Paul Laurin
Corporate Officer/Principal presso ViRexx Medical Corp.
Posizioni attive di Jean-Paul Laurin
Società | Posizione | Inizio | Fine |
---|---|---|---|
ViRexx Medical Corp.
![]() ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada. | Corporate Officer/Principal | - | - |
Storia della carriera di Jean-Paul Laurin
Statistiche
Distribuzione geografica
Canada | 2 |
Posizioni
Corporate Officer/Principal | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
ViRexx Medical Corp.
![]() ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada. | Health Technology |
- Borsa valori
- Insiders
- Jean-Paul Laurin
- Esperienza